Risk of dying from Covid-19 40 times the risk of rare blood clot after receiving J&J vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
A blood clot is less risky than Covid says CDC

The risk of dying from Covid-19 is 40 times the risk of developing a rare blood clotting condition after getting the Johnson & Johnson vaccine, a CNN analysis shows.

The US Centers for Disease Control and Prevention said Wednesday it has received reports of 28 people who have developed a rare blood clotting syndrome out of 8.7 million given J&J's Janssen coronavirus vaccine. Three of them have died from the condition, known as thrombosis with thrombocytopenia syndrome (TTS).

However, in that same time period -- March 2 to May 7 -- more than 2.2 million people were diagnosed with Covid-19 and more than 43,000 died, according to data from Johns Hopkins University.
In a group of about 8.7 million people, that scales to nearly 59,000 new Covid-19 cases reported in the past two months and nearly 1,150 new Covid-19 deaths, more than 40 times the number of reported and confirmed cases of TTS.

The chances that a person vaccinated with the J&J vaccine will develop TTS are less than one in 300,000, according to CDC data. But in the past two months, about one in every 7,600 Americans has died of Covid-19.
The CDC has said TTS is plausibly linked to J&J's Janssen vaccine but has said the benefits of the vaccine nonetheless outweigh the risk. All cases have been seen in people ages 18 to 59.

"Most of these TTS cases are occurring in the 30-49-year-old age group," CDC's Dr. Tom Shimabukuro told a meeting of the CDC's Advisory Committee on Immunization Practices.

While most cases were among women, six cases were reported among men, Shimabukuro said. He said 19 had a type of brain blood clot called thrombosis of the cerebral venous sinus, or CVST, while others had different types of blood clots.

The CDC has alerted doctors and patients about the possibility of the complication so it can be recognized and treated promptly and properly.
"There were no cases with a known or documented coagulation disorder," Shimabukuro said. That indicates it's difficult to predict who might develop the condition.
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

"It is important to recognize TTS early and initiate appropriate treatment," he added. "TTS is a rare, clinically serious and life-threatening condition."
TTS has also been linked to AstraZeneca's coronavirus vaccine, which is not authorized for use in the US but is in wide use in Britain and Europe.

Tags : #JJVaccine #Covid19Vaccine #JohnsonandJohnson #CDC #FDA #CovidVaccine

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026